Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobemstomig (RO7247669) + nab-paclitaxel vs pembrolizumab + nab-paclitaxel in PD-L1-positive metastatic TNBC
2022-502457-34-00Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Tobemstomig + nab-paclitaxel with Pembrolizumab + nab-paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Mar 2024; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2022-502457-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502457-34-00.